482 related articles for article (PubMed ID: 10952487)
21. Radioimmunotherapy of human colonic cancer xenografts with 90Y labeled monoclonal antibodies to carcinoembryonic antigen.
Sharkey RM; Kaltovich FA; Shih LB; Fand I; Govelitz G; Goldenberg DM
Cancer Res; 1988 Jun; 48(11):3270-5. PubMed ID: 3365705
[TBL] [Abstract][Full Text] [Related]
22. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
Casey JL; Pedley RB; King DJ; Green AJ; Yarranton GT; Begent RH
Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
[TBL] [Abstract][Full Text] [Related]
23. Radioimmunotherapy of human glioma xenografts in nude mice by indium-111 labelled internalising monoclonal antibody.
Saga T; Sakahara H; Nakamoto Y; Sato N; Zhao S; Aoki T; Miyatake S; Namba Y; Konishi J
Eur J Cancer; 1999 Aug; 35(8):1281-5. PubMed ID: 10615242
[TBL] [Abstract][Full Text] [Related]
24. Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments.
Casey JL; King DJ; Chaplin LC; Haines AM; Pedley RB; Mountain A; Yarranton GT; Begent RH
Br J Cancer; 1996 Nov; 74(9):1397-405. PubMed ID: 8912535
[TBL] [Abstract][Full Text] [Related]
25. Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM).
Antoniw P; Farnsworth AP; Turner A; Haines AM; Mountain A; Mackintosh J; Shochat D; Humm J; Welt S; Old LJ; Yarranton GT; King DJ
Br J Cancer; 1996 Aug; 74(4):513-24. PubMed ID: 8761364
[TBL] [Abstract][Full Text] [Related]
26. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.
Sharkey RM; Behr TM; Mattes MJ; Stein R; Griffiths GL; Shih LB; Hansen HJ; Blumenthal RD; Dunn RM; Juweid ME; Goldenberg DM
Cancer Immunol Immunother; 1997 May; 44(3):179-88. PubMed ID: 9191878
[TBL] [Abstract][Full Text] [Related]
27. Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis.
Santoro L; Boutaleb S; Garambois V; Bascoul-Mollevi C; Boudousq V; Kotzki PO; Pèlegrin M; Navarro-Teulon I; Pèlegrin A; Pouget JP
J Nucl Med; 2009 Dec; 50(12):2033-41. PubMed ID: 19910417
[TBL] [Abstract][Full Text] [Related]
28. Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody.
Stein R; Govindan SV; Hayes M; Griffiths GL; Hansen HJ; Horak ID; Goldenberg DM
Clin Cancer Res; 2005 Apr; 11(7):2727-34. PubMed ID: 15814655
[TBL] [Abstract][Full Text] [Related]
29. Intraperitoneal 131I- and 90Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry.
Stewart JS; Hird V; Snook D; Sullivan M; Myers MJ; Epenetos AA
Int J Cancer Suppl; 1988; 3():71-6. PubMed ID: 3209303
[TBL] [Abstract][Full Text] [Related]
30. 131I-Lym-1 in mice implanted with human Burkitt's lymphoma (Raji) tumors: loss of tumor specificity due to radiolysis.
DeNardo GL; DeNardo SJ; Wessels BW; Kukis DL; Miyao N; Yuan A
Cancer Biother Radiopharm; 2000 Dec; 15(6):547-60. PubMed ID: 11190487
[TBL] [Abstract][Full Text] [Related]
31. Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel.
Govindan SV; Stein R; Qu Z; Chen S; Andrews P; Ma H; Hansen HJ; Griffiths GL; Horak ID; Goldenberg DM
Breast Cancer Res Treat; 2004 Mar; 84(2):173-82. PubMed ID: 14999147
[TBL] [Abstract][Full Text] [Related]
32. Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with beta-particle emitters.
Govindan SV; Goldenberg DM; Elsamra SE; Griffiths GL; Ong GL; Brechbiel MW; Burton J; Sgouros G; Mattes MJ
J Nucl Med; 2000 Dec; 41(12):2089-97. PubMed ID: 11138697
[TBL] [Abstract][Full Text] [Related]
33. Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse.
Sato N; Saga T; Sakahara H; Yao Z; Nakamoto Y; Zhang M; Kuroki M; Matsuoka Y; Iida Y; Konishi J
J Nucl Med; 1999 Apr; 40(4):685-92. PubMed ID: 10210230
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
[TBL] [Abstract][Full Text] [Related]
35. Successful therapy of a human lung cancer xenograft using MAb RS7 labeled with residualizing radioiodine.
Stein R; Govindan SV; Chen S; Reed L; Spiegelman H; Griffiths GL; Hansen HJ; Goldenberg DM
Crit Rev Oncol Hematol; 2001; 39(1-2):173-80. PubMed ID: 11418314
[TBL] [Abstract][Full Text] [Related]
36. Comparative biodistribution and radioimmunotherapy of monoclonal antibody RS7 and its F(ab')2 in nude mice bearing human tumor xenografts.
Stein R; Blumenthal R; Sharkey RM; Goldenberg DM
Cancer; 1994 Feb; 73(3 Suppl):816-23. PubMed ID: 8306265
[TBL] [Abstract][Full Text] [Related]
37. Thyroid radiation doses during radioimmunotherapy of CEA-expressing tumours with 131I-labelled monoclonal antibodies.
Behr TM; Juweid ME; Sharkey RM; Dunn RM; Ying Z; Becker WS; Siegel JA; Goldenberg DM
Nucl Med Commun; 1996 Sep; 17(9):767-80. PubMed ID: 8895904
[TBL] [Abstract][Full Text] [Related]
38. Pre-targeted radioimmunotherapy of human colon cancer xenografts in athymic mice using streptavidin-CC49 monoclonal antibody and 90Y-DOTA-biotin.
Domingo RJ; Reilly RM
Nucl Med Commun; 2000 Jan; 21(1):89-96. PubMed ID: 10717908
[TBL] [Abstract][Full Text] [Related]
39. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts.
Sharkey RM; Motta-Hennessy C; Pawlyk D; Siegel JA; Goldenberg DM
Cancer Res; 1990 Apr; 50(8):2330-6. PubMed ID: 2180566
[TBL] [Abstract][Full Text] [Related]
40. Comparative binding and preclinical localization and therapy studies with radiolabeled human chimeric and murine 17-1A monoclonal antibodies.
Buchsbaum DJ; Brubaker PG; Hanna DE; Glatfelter AA; Terry VH; Guilbault DM; Steplewski Z
Cancer Res; 1990 Feb; 50(3 Suppl):993s-999s. PubMed ID: 2297753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
